A safety evaluation of raltegravir for the treatment of HIV

References

• World Health Organization. Global Health Observatory (GHO) data [cited 2017 Aug 19]. Available from: http://apps.who.int/gho/data/view.main.22100WHO?lang=en
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [cited 2017 Aug 19]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• EACS Guidelines version 8.2. 2017 Jan [cited 2017 Aug 19]. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs. 2006 Dec;15(12):1507–1522.
   PubMed Web of Science ®Google Scholar
• Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008 Sep 25;51(18):5843–5855. DOI:10.1021/jm800245z.
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005 Mar;4(3):236–248.
   PubMed Web of Science ®Google Scholar
• Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010 Mar 11;464(7286):232–236. DOI:10.1038/nature08784.
   PubMed Web of Science ®Google Scholar
• Pendri A, Meanwell NA, Peese KM, et al. New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opin Ther Pat. 2011 Aug;21(8):1173–1189. DOI:10.1517/13543776.2011.586631.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Isentress (raltegravir). Product information. Annex I: Summary of product characteristics; [cited 2017 Sep 5]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000860/WC500037405.pdf
   Google Scholar
• Merck. Isentress (package insert); [cited 2017 Sep 5]. Available from: https://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf
   Google Scholar
• Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852–2856.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47:137–140.
   PubMed Web of Science ®Google Scholar
• Krishna R, East L, Larson P, et al. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose. Biopharm Drug Dispos. 2016 Dec;37(9):533–541. DOI:10.1002/bdd.2043.
   PubMed Web of Science ®Google Scholar
• Anderson MS, Mabalot Luk JA, Hanley WD, et al. Effect of raltegravir on the pharmacokinetics of methadone. J Clin Pharmacol. 2010 Dec;50(12):1461–1466. DOI:10.1177/0091270009360981.
   PubMed Web of Science ®Google Scholar
• Tittle V, Bull L, Boffito M, et al. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. Clin Pharmacokinet. 2015 Jan;54(1):23–34. DOI:10.1007/s40262-014-0204-8.
   PubMed Web of Science ®Google Scholar
• Khatri A, Dutta S, Dunbar M, et al. Evaluation of drug-drug interactions between direct-acting antihepatitis C virus combination regimens and the HIV-1 antiretroviral agents raltegravir, tenofovir, emtricitabine, efavirenz, and rilpivirine. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2965–2971. DOI:10.1128/AAC.02605-15.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother. 2009 May;53(5):1747–1752. Epub 2009 Feb 17. DOI:10.1128/AAC.01194-08.
   PubMed Web of Science ®Google Scholar
• Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States; [cited 2017 Sep 13]:[C-23 p.]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf
   Google Scholar
• Maliakkal A, Walmsley S, Tseng A. Review of the efficacy, safety, and pharmacokinetics of raltegravir in pregnancy. J Acquir Immune Defic Syndr. 2016;72:153–161.
   PubMed Web of Science ®Google Scholar
• Brites C, Nobrega I, Travassos AG et al. Raltegravir vs. lopinavir/r for late-presenters pregnant women. 9th International AIDS Society (IAS) Conference on HIV Science (IAS 2017); 2017 Jul 23–26; Paris. Oral Abstract WEAC0201.
   Google Scholar
• Thepnarong N, Puthanakit T, Chaithongwongwatthana S, et al. Intensification of antiretroviral treatment with raltegravir for late-presenting HIV-infected pregnant women. In: 9th International AIDS Society (IAS) Conference on HIV Science. 2017 Jul 23-26; Paris. Oral Abstract WEAC0202.
   Google Scholar
• Clarke D, Acosta E, Chain A et al. Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: dose-finding study. Conference on Retroviruses and Opportunistic Infections;2017 Feb 13–16; Seattle. Abstract Number 757.
   Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63:77–85.
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009 Sep 5;374(9692):796–806. DOI:10.1016/S0140-6736(09)60918-1.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials. 2012 Jul–Aug;13(4):228–232. DOI:10.1310/hct1304-228.
   PubMed Web of Science ®Google Scholar
• Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461–471. DOI:10.7326/M14-1084.
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Mar 2;381(9868):735–743. DOI:10.1016/S0140-6736(12)61853-4.
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov;13(11):927–935. DOI:10.1016/S1473-3099(13)70257-3.
   PubMed Web of Science ®Google Scholar
• Cahn P, Kaplan R, Sax PE, et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 Sep 11. pii: S2352-3018(17)30128-5. DOI:10.1016/S2352-3018(17)30128-5.
   PubMed Web of Science ®Google Scholar
• Cahn P, Kaplan R, Sax PE et al. Raltegravir (RAL) 1200 mg once daily (QD) versus RAL 400 mg twice daily (BID), in combination with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in previously untreated HIV-1 infection through week 96. 9th International AIDS Society (IAS) Conference on HIV Science (IAS 2017); 2017 July 23–26; Paris. Poster TULBPEB20.
   Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013 Feb;29(2):256–265. DOI:10.1089/AID.2011.0275.
   PubMed Web of Science ®Google Scholar
• Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014 Nov 29;384(9958):1942–1951. DOI:10.1016/S0140-6736(14)61170-3.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–365.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50:605–612.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013 Jul;13(7):587–596. DOI:10.1016/S1473-3099(13)70093-8.
   PubMed Web of Science ®Google Scholar
• Cossarini F, Castagna A, Lazzarin A. Raltegravir in treatment naive patients. Eur J Med Res. 2009;14(Suppl. III):22–29.
   PubMedGoogle Scholar
• Fransen S, Gupta S, Frantzell A, et al. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol. 2012 Jul;86(13):7249–7255. DOI:10.1128/JVI.06618-11.
   PubMed Web of Science ®Google Scholar
• Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis. 2012;25:677–686.
   PubMed Web of Science ®Google Scholar
• Shafer RW. Human immunodeficiency virus type 1 drug resistance mutations update. J Infect Dis. 2017 Sep:15. DOI:10.1093/infdis/jix398.
   Web of Science ®Google Scholar
• Anstett K, Brenner B, Mesplede T, et al. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017 Jun 5;14(1):36. DOI:10.1186/s12977-017-0360-7.
   PubMedGoogle Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010 Jan 30;375(9712):396–407. DOI:10.1016/S0140-6736(09)62041-9.
   PubMed Web of Science ®Google Scholar
• Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. Aids. 2010 Jul 17;24(11):1697–1707. DOI:10.1097/QAD.0b013e32833a608a.
   PubMed Web of Science ®Google Scholar
• Amin J, Boyd MA, Kumarasamy N, et al. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS One. 2015 Feb 27;10(2):e0118228. DOI:10.1371/journal.pone.0118228.
   PubMed Web of Science ®Google Scholar
• Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014 Jul 17;371(3):234–247. DOI:10.1056/NEJMoa1311274.
   PubMed Web of Science ®Google Scholar
• La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV. 2016 Jun;3(6):e247–58. DOI:10.1016/S2352-3018(16)30011-X.
   PubMed Web of Science ®Google Scholar
• Kanters S, Socias ME, Paton NI, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. Lancet HIV. 2017 Oct;4(10):e433–e441. DOI:10.1016/S2352-3018(17)30109-1.
   PubMed Web of Science ®Google Scholar
• Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016. [cited 2017 Sep 13]:[150 p.]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK374294/
   Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012 Jan;12(1):27–35. DOI:10.1016/S1473-3099(11)70249-3.
   PubMed Web of Science ®Google Scholar
• Elion R, Molina JM, Ramón Arribas López J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):494–497. DOI:10.1097/QAI.0b013e318298469c.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013 Aug 24;382(9893):700–708. DOI:10.1016/S0140-6736(13)61221-0.
   PubMed Web of Science ®Google Scholar
• Teppler H, Brown DD, Leavitt RY, et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011;9:40–53.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 Jun 15;60(12):1842–1851. DOI:10.1093/cid/civ193.
   PubMed Web of Science ®Google Scholar
• Perry ME, Almaani N, Desai N, et al. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome – implications for clinical practice and patient safety. Int J STD AIDS. 2013 Aug;24(8):639–642. DOI:10.1177/0956462413481528.
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Benatti SV, Di Filippo E, et al. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. Aids. 2014 Apr 24;28(7):1077–1079. DOI:10.1097/QAD.0000000000000204.
   PubMed Web of Science ®Google Scholar
• Loulergue P, Mir O. Raltegravir-induced DRESS syndrome. Scand J Infect Dis. 2012 Oct;44(10):802–803.
   PubMed Web of Science ®Google Scholar
• Thomas M, Hopkins C, Duffy E, et al. Association of the HLA-B*53:01 allele with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. Clin Infect Dis. 2017 May 1;64(9):1198–1203. DOI:10.1093/cid/cix096.
   PubMed Web of Science ®Google Scholar
• Dori L, Buonomini AR, Viscione M, et al. A case of rhabdomiolysis associated with raltegravir use. Aids. 2010 Jan 28;24(3):473–475. DOI:10.1097/QAD.0b013e328334cc4a.
   PubMed Web of Science ®Google Scholar
• Lee FJ, Amin J, Bloch M, et al. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):525–533.
   PubMed Web of Science ®Google Scholar
• Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 2015 Mar;45(3):289–294. DOI:10.1016/j.ijantimicag.2014.10.013.
   PubMed Web of Science ®Google Scholar
• Croce F, Vitello P, Dalla Pria A, et al. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS. 2010 Nov;21(11):783–785. DOI:10.1258/ijsa.2010.010246.
   PubMed Web of Science ®Google Scholar
• Calza L, Danese I, Colangeli V, et al. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. AIDS Res Hum Retroviruses. 2014 Dec;30(12):1162–1169. DOI:10.1089/aid.2014.0113.
   PubMed Web of Science ®Google Scholar
• Monteiro P, Perez I, Pich J, et al. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother. 2013 Feb;68(2):404–408. Epub 2012 Oct 28. DOI:10.1093/jac/dks416.
   PubMed Web of Science ®Google Scholar
• Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med. 2012 Feb;13(2):127–131. DOI:10.1111/j.1468-1293.2011.00933.x.
   PubMed Web of Science ®Google Scholar
• van Halsema C, Whitfield T, Lin N, et al. Five years’ real-life experience with raltegravir in a large HIV centre. Int J STD AIDS. 2016 Apr;27(5):387–393. DOI:10.1177/0956462415584485.
   PubMed Web of Science ®Google Scholar
• Hurt CB, Napravnik S, Moore RD, et al. Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C. Antivir Ther. 2014;19(4):415–422.
   PubMed Web of Science ®Google Scholar
• Neukam K, Mira JA, Collado A, et al. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: the HEPAVIR SEG-HEP cohort. PLoS One. 2016 Feb 5;11(2):e0148104. DOI:10.1371/journal.pone.
   PubMed Web of Science ®Google Scholar
• Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother. 2010 Mar;65(3):543–547. DOI:10.1093/jac/dkp446.
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014;14:459–467.
   PubMed Web of Science ®Google Scholar
• Taburet A-M, Sauvageon H, Grinsztejn B, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. Clin Infect Dis. 2015;61:1328–1335.
   PubMed Web of Science ®Google Scholar
• Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016 Nov;3(11):e510–e520. DOI:10.1016/S2352-3018(16)30091-1.
   PubMed Web of Science ®Google Scholar
• Ford N, Shubber Z, Pozniak A, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69:422–429.
   PubMed Web of Science ®Google Scholar
• Macías J, Mancebo M, Merino D, et al. Changes in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus-infected patients with nonalcoholic fatty liver disease. Clin Infect Dis. 2017 Sep 15;65(6):1012–1019. DOI:10.1093/cid/cix467.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Mi D, Moe SM, et al. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):279–283.
   PubMed Web of Science ®Google Scholar
• Jotwani V, Atta MG, Estrella MM. Kidney disease in HIV: moving beyond HIV-associated nephropathy. J Am Soc Nephrol. 2017 Aug 7. pii: ASN.2017040468. DOI:10.1681/ASN.2017040468.
   PubMedGoogle Scholar
• Bernardino JI, Mocroft A, Mallon PW, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015 Nov;2(11):e464–73. DOI:10.1016/S2352-3018(15)00181-2.
   PubMed Web of Science ®Google Scholar
• Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted darunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One. 2014;9(8):e106221.
   PubMed Web of Science ®Google Scholar
• Calza L, Magistrelli E, Colangeli V, et al. Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study. Antiviral Therapy. 2016;21:217–224.
   PubMed Web of Science ®Google Scholar
• Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2016:1–6.
   PubMedGoogle Scholar
• de Boer M, van den Berk G, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. Aids. 2016;30:2831–2834.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56–63.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Madeddu G, Gulminetti R, et al. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. Aids. 2017 Jan 28;31(3):455–457. DOI:10.1097/QAD.0000000000001351.
   PubMed Web of Science ®Google Scholar
• Menard A, Montagnac C, Solas C, et al. Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. Aids. 2017 May 15;31(8):1201–1203. DOI:10.1097/QAD.0000000000001459.
   PubMed Web of Science ®Google Scholar
• Viswanathan P, Baro E, Soon G, et al. Neuropsychiatric adverse events associated with integrase strand transfer inhibitors. Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13–16; Seattle. Session Number: P-F4 Abstract 372.
   Google Scholar
• Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. Aids. 2017 Aug 24;31(13):1853–1858. DOI:10.1097/QAD.0000000000001590.
   PubMed Web of Science ®Google Scholar
• Peñafiel J, De Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017 Jun 1;72(6):1752–1759. DOI:10.1093/jac/dkx053.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Esteve A, Miro JP, et al. Discontinuation of DTG, EVG/c, and RAL due to toxicity in a prospective cohort. Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13–16; Seattle. Session Number: P-O2. Abstract 651.
   Google Scholar
• Hsu R, Fusco J, Henegar C, et al. Psychiatric disorders observed in HIV+ patients using 6 common 3rd agents in OPERA. Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13–16; Seattle. Session Number: P-O4. Abstract 664.
   Google Scholar